CytomX Therapeutics Inc (NASDAQ: CTMX) on Monday, soared 129.43% from the previous trading day, before settling in for the closing price of $0.93. Within the past 52 weeks, CTMX’s price has moved between $0.40 and $2.05.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 36.21% over the last five years. The company achieved an average annual earnings per share of -74.47%. With a float of $78.64 million, this company’s outstanding shares have now reached $80.10 million.
The firm has a total of 121 workers. Let’s measure their productivity. In terms of profitability, gross margin is 99.03%, operating margin of 18.1%, and the pretax margin is 23.24%.
CytomX Therapeutics Inc (CTMX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of CytomX Therapeutics Inc is 2.46%, while institutional ownership is 58.10%. The most recent insider transaction that took place on Mar 18 ’25, was worth 22,556. In this transaction CEO of this company sold 37,656 shares at a rate of $0.60, taking the stock ownership to the 995,195 shares. Before that another transaction happened on Mar 18 ’25, when Company’s Chief Financial Officer sold 8,551 for $0.60, making the entire transaction worth $5,122. This insider now owns 201,026 shares in total.
CytomX Therapeutics Inc (CTMX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -74.47% per share during the next fiscal year.
CytomX Therapeutics Inc (NASDAQ: CTMX) Trading Performance Indicators
CytomX Therapeutics Inc (CTMX) is currently performing well based on its current performance indicators. A quick ratio of 1.25 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.24.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.39, a number that is poised to hit 0.02 in the next quarter and is forecasted to reach -0.53 in one year’s time.
Technical Analysis of CytomX Therapeutics Inc (CTMX)
Analysing the last 5-days average volume posted by the [CytomX Therapeutics Inc, CTMX], we can find that recorded value of 28.08 million was better than the volume posted last year of 3.21 million. As of the previous 9 days, the stock’s Stochastic %D was 74.72%. Additionally, its Average True Range was 0.19.
During the past 100 days, CytomX Therapeutics Inc’s (CTMX) raw stochastic average was set at 97.19%, which indicates a significant increase from 96.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 356.73% in the past 14 days, which was higher than the 163.28% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.7000, while its 200-day Moving Average is $0.9700. Now, the first resistance to watch is $2.3200. This is followed by the second major resistance level at $2.5200. The third major resistance level sits at $2.8500. If the price goes on to break the first support level at $1.7900, it is likely to go to the next support level at $1.4600. Now, if the price goes above the second support level, the third support stands at $1.2600.
CytomX Therapeutics Inc (NASDAQ: CTMX) Key Stats
Market capitalization of the company is 171.72 million based on 80,621K outstanding shares. Right now, sales total 138,100 K and income totals 31,870 K. The company made 38,090 K in profit during its latest quarter, and 18,880 K in sales during its previous quarter.
